Esperion Therapeutics Shares Soar 4.65% on Revenue Growth

Esperion Therapeutics, Inc. (ESPR) shares surged 4.65% in pre-market trading on April 4, 2025, reflecting a positive sentiment among investors.

Esperion Therapeutics, Inc. (ESPR) has a Zacks Rank #3 (Hold), indicating a neutral outlook for the stock in the near term. Analysts expect the company to report earnings of -$0.18 per share in its upcoming earnings release on May 6, 2025.

The company's financial performance shows strong revenue growth, with a year-over-year increase of 114.30%. This robust growth is supported by a gross margin of 62.91%, highlighting Esperion's operational efficiency. The stock's price-to-sales ratio stands at 0.83x, suggesting that the market values the company's sales at a reasonable level.

Esperion Therapeutics has a significant short interest, with 28.90 million shares shorted, representing 14.87% of the float. This high short interest could indicate bearish sentiment among some investors, but it also presents an opportunity for a short squeeze if the stock price continues to rise.